Sionna Therapeutics completes Phase 1 dosing of new drugs, strong financial position.

From GlobeNewswire: 2025-05-12 07:00:00

Sionna Therapeutics completes Phase 1 dosing for NBD1 stabilizers SION-719 & SION-451, demonstrating good tolerance. Phase 1 topline data expected this quarter. Phase 2a and dual combination trials scheduled for second half of 2025. Strong cash position of $354.7 million to fund operations into 2028 post IPO. Shares traded under Nasdaq: SION.

Financial results show Research and Development expenses at $13.7 million, General and Administrative expenses at $6.0 million, and a net loss of $16.5 million for the first quarter of 2025. Cash, cash equivalents, and marketable securities total $354.7 million as of March 31, 2025, with expected funding until 2028.

Sionna Therapeutics, a biopharmaceutical company, focuses on developing medicines to normalize the function of the CFTR protein for cystic fibrosis patients. Pipeline includes NBD1 stabilizers and complementary CFTR modulators. Forward-looking statements caution risks and uncertainties. Presentation at 48th European Cystic Fibrosis Conference on June 4-7, 2025, in Milan, Italy.



Read more at GlobeNewswire:: Sionna Therapeutics Reports First Quarter 2025 Financial